EUCTR2014-004692-22-IT进行中（未招募）1 期
MARAT Study Pharmacokinetics of MARaviroc and boosted ATazanavir dual regimen in stable HIV-infected patients” - MARAT
niversity of Torino0 个研究点目标入组 30 人开始时间: 2015年1月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-age>18 years;
- •-confirmed HIV-antibodies positivity;
- •-signed informed consent;
- •-HIV-RNA<20 cp/ml for last 24 months, at least;
- •-no virological failures to PI regimens;
- •-no major PI resistance associated mutations;
- •-genotypic tropism for CCR5 co-receptor.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •-active opportunistic infections or neoplasms;
- •-need for drugs with known drug to drug interactions with included drugs (rifampicin, proton pump inhibitors);
- •-liver cirrhosis;
- •-any evidence of tropism for CXCR4 or dual infection.
研究者
相似试验
撤回
3 期
Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected PatientsHIV InfectionNCT03708861University of Turin, Italy
已完成
1 期
Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 InfectionHIV InfectionsNCT02778204National Institute of Allergy and Infectious Diseases (NIAID)47
进行中（未招募）
不适用
PILOT STUDY OF NOVEL COMBINATION OF MARAVIROC + ATAZANAVIR/RITONAVIR VS ATAZANAVIR/RITONAVIR + EMTRICITABINE/TENOFOVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2008-007038-24-DEViiV Healthcare UK Limited88
已完成
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese ParticipantsHealthy VolunteersNCT04497883Shire24
进行中（未招募）
1 期
Study of the use of anti_HIV drugs with reduced neuronal toxicity (including maraviroc) in patients with neurocogntive disordersEUCTR2016-003741-29-ITA.S.L. TO 276